Evidence map›Paper›PMID 35082911›Full record

ArticleComputational and mathematical methods in medicine2022

miR-335-5p Inhibits Progression of Uterine Leiomyoma by Targeting ARGLU1.

Wei Zhao, Yingyan Zhao, Ling Chen, Yan Sun, Sumei Fan

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Retracted: miR-335-5p Inhibits Progression of Uterine Leiomyoma by Targeting ARGLU1.Computational and mathematical methods in medicine · 2023
    Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wei ZhaoDepartment of Clinical Laboratory, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 123 Tianfei Lane, Mochou Road, Nanjing, Jiangsu 210004, China.ORCID https://orcid.org/0000-0003-3048-5873
Yingyan ZhaoDepartment of Obstetrics and Gynecology, Zhangjiagang Hospital of Traditional Chinese Medicine & Affiliated Zhangjiagang Hospital of Nanjing University of Chinese Medicine, Zhangjiagang 215600, China.ORCID https://orcid.org/0000-0002-7063-3343
Ling ChenDepartment of Obstetrics and Gynecology, Zhangjiagang Hospital of Traditional Chinese Medicine & Affiliated Zhangjiagang Hospital of Nanjing University of Chinese Medicine, Zhangjiagang 215600, China.ORCID https://orcid.org/0000-0001-8090-6766
Yan SunDepartment of Obstetrics and Gynecology, Zhangjiagang Hospital of Traditional Chinese Medicine & Affiliated Zhangjiagang Hospital of Nanjing University of Chinese Medicine, Zhangjiagang 215600, China.ORCID https://orcid.org/0000-0001-8491-590X
Sumei FanDepartment of Geriatrics, The Affiliated Huai'an Hospital of Xuzhou Medical University and the Second People's Hospital of Huai'an, No. 62, Huaihai Road (S.), Huaian, Jiangsu 223002, China.ORCID https://orcid.org/0000-0001-7095-1299
Nanjing University of Chinese Medicine · CNNanjing Maternity and Child Health Care Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies have demonstrated that miR-335-5p exhibits an essential role in the progress of multiple tumors, including thyroid cancer, pancreatic cancer, and non-small-cell lung cancer. However, the possible expression, the detailed role, and the underlying mechanisms of miR-335-5p in uterine leiomyoma (UL) still remained unclear. Therefore, the present study was designed to investigate the mechanism and function of miR-335-5p in UL. In our study, microRNA-335-5p (miR-335-5p) is significantly downregulated in UL tissues and UL cell lines, especially in HCC1688 and SK-UT-1 cells. Functionally, overexpression of miR-335-5p notably inhibits the viability of UL cell lines by CCK-8 assay. Besides, upregulation of miR-335-5p inhibits proliferation of UL cell lines by colony formation assay and decreases the protein levels of PCNA and Ki-67 detected by western blot assay. In addition, overexpression of miR-335-5p induces UL cell cycle arrest at G1 phase. Upregulation of miR-335-5p decreases the levels of Cyclin A1, Cyclin B1, and Cyclin D2 and upregulates the expression of p27 protein. Additionally, upregulation of miR-335-5p promotes the apoptosis of UL cell lines, increases the protein levels of Bax, Cleaved caspase-3, and Cleaved caspase-9, and decreases the protein expression of Bcl-2. Moreover, Arginine and Glutamate-Rich protein 1 (ARGLU1) is predicted as a target of miR-335-5p by ENCORI and miRDB and confirmed by dual-luciferase reporter assay. ARGLU1 is negatively associated with miR-335-5p. Furthermore, overexpression of ARGLU1 partly restores the effects of miR-335-5p mimic on the viability, proliferation, cell cycle, and apoptosis of UL cell lines. To conclude, miR-335-5p may play a repressive role in UL by targeting ARGLU1 and serve as a potential therapeutic target for the treatment of UL.

Indexed as

AdultApoptosisBiomarkers, TumorCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalComputational BiologyDisease ProgressionDown-RegulationFemaleGene Expression Regulation, NeoplasticGene TargetingHumansIntracellular Signaling Peptides and ProteinsLeiomyomaARGLU1 protein, humanBiomarkers, TumorIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN335 microRNA, human

Identifiers

PMID35082911
PMCPMC8786540
OpenAlexW4205696759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.